Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression

NCT05414422 is registered in ClinicalTrials.gov with Perception Neuroscience as lead sponsor.

NCT NCT05414422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05414422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression
Lead sponsor
Perception Neuroscience
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2022
Completion date
November 10, 2022
Enrollment
102 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression